NUWELLIS INC (NUWE)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.78+6.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · NUWE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -87.8% |
| Our one-year growth estimate | diamond | 18.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 106.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
NUWE — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to
Why it matters: Successful integration can make products better. It can also help the company grow.
Watch forThere are good updates on integrating Rendiatech. This shows progress in product and market plans.
Also watch forThere is negative news about integration problems or delays. This may hurt the growth strategy.
Why it matters: A successful FDA submission can open new markets. This could greatly increase revenue.
Supportive ifThe FDA submission for Aquadex label expansion will be done by December 2026.
Worry ifSubmission is delayed beyond December 2026.
Why it matters: A drop in revenue growth would signal weakening demand for Nuwellis' products.
Worry ifQ3 revenue growth below 14% year over year would confirm a slowdown.
Less concerning ifQ3 revenue growth at or above 14% year over year would show continued strength.
Why it matters: A new CEO can change company strategy. This affects future performance.
Watch forThe new CEO announces a clear growth strategy within three months.
Also watch forThe new CEO provides no new strategic direction or clarity.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$457 on $10,000 · ±4.6% | How much price usually moves either way. |
| Bad day | $1,470 loss on $10,000 · 14.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,957 loss on $10,000 · 99.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better operating income shows that the company is managing costs well. It also means the company is working more efficiently.
Supportive ifOperating income improves to less than -$4 million in Q2 2026.
Worry ifOperating income worsens to more than -$4.5 million in Q2 2026.
Why it matters: Higher gross margins mean better pricing and cost control. This can help make more money.
Supportive ifGross margin exceeds 80% in Q3.
Worry ifGross margin drops below 70% in Q3.
Why it matters: Strong revenue growth signals that the company is successfully expanding its market presence. This is crucial for long-term viability.
Supportive ifQ3 revenue growth exceeds 20% year over year.
Worry ifQ3 revenue growth falls below 15% year over year.
Why it matters: The acquisition aims to boost growth. Revenue impact shows if it is working.
Supportive ifRevenue from the Rendiatech acquisition exceeds $2.4M in Q2 2026.
Worry ifRevenue from the acquisition stays flat or declines in Q2 2026.
Why it matters: Gross profit growth shows operational efficiency. It is a key measure of success.
Supportive ifGross profit exceeds $1.68M in Q2 2026.
Worry ifGross profit stays at or below $1.68M in Q2 2026.
Why it matters: More capital raises may show cash flow problems or chances for growth.
Watch forNew capital raises over $12.7 million would show strong demand.
Also watch forNo new capital raises or less cash would show financial problems.